Amryt Pharma PLC (AMYT)

NASDAQ: AMYT · IEX Real-Time Price · USD
7.16
+0.01 (0.14%)
At close: Dec 5, 2022 3:40 PM
7.23
+0.07 (0.98%)
After-hours: Dec 5, 2022 4:44 PM EST
0.14%
Market Cap 457.40M
Revenue (ttm) 243.62M
Net Income (ttm) -790,000
Shares Out 320.88M
EPS (ttm) 0.38
PE Ratio 18.84
Forward PE 67.57
Dividend n/a
Ex-Dividend Date n/a
Volume 320,142
Open 7.16
Previous Close 7.15
Day's Range 7.03 - 7.26
52-Week Range 5.61 - 11.63
Beta 0.39
Analysts n/a
Price Target 36.48 (+409.5%)
Earnings Date Nov 3, 2022

About AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal ... [Read more]

Industry Drug Manufacturers-Specialty & Generic
Founded 2015
Employees 289
Stock Exchange NASDAQ
Ticker Symbol AMYT
Full Company Profile

Financial Performance

Financial Statements

News

European Commission approves Mycapssa® for the treatment of Acromegaly

European Commission approves Mycapssa ® for the t reatment of Acromegaly

12 hours ago - GlobeNewsWire

Amryt Announces New Patent for Mycapssa®

Amryt Announces New Patent for Mycapssa ®

5 days ago - GlobeNewsWire

New Strong Sell Stocks for November 17th

BRFS, AOS and AMYT have been added to the Zacks Rank #5 (Strong Sell) List on November 17, 2022.

Other symbols: AOSBRFS
2 weeks ago - Zacks Investment Research

New Strong Sell Stocks for November 16th

EGO, BRFS and AMYT have been added to the Zacks Rank #5 (Strong Sell) List on November 16, 2022.

Other symbols: BRFSEGO
2 weeks ago - Zacks Investment Research

New Strong Sell Stocks for November 10th

AMYT, CHRD and BKI have been added to the Zacks Rank #5 (Strong Sell) List on November 10, 2022.

Other symbols: BKICHRD
3 weeks ago - Zacks Investment Research

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Lags Revenue Estimates

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of -50% and 7.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

1 month ago - Zacks Investment Research

Amryt Supports Acromegaly Awareness Day 2022

Amryt Supports Acromegaly Awareness Day 202 2

1 month ago - GlobeNewsWire

Amryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Amryt Pharma PLC Sponsored ADR (AMYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

The British Journal of Dermatology Publishes Results from Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa

The British Journal of Dermatology Publishes Results f rom Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa

1 month ago - GlobeNewsWire

Amryt Supports Global EB Awareness Week 2022

Amryt Supports Global EB Awareness Week 202 2

1 month ago - GlobeNewsWire

Amryt to Report Q3 2022 Results on November 3, 2022

A mryt to Report Q 3 202 2 Results on November 3 , 2022

1 month ago - GlobeNewsWire

COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly

COMP adopts positive opinion on O rphan D isease D esignation for Mycapssa® for the treatment of Acromegaly

1 month ago - GlobeNewsWire

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)

1 month ago - GlobeNewsWire

Amryt Supports FH Awareness Day – September 24, 2022

Amryt Supports FH Awareness Day – September 24, 202 2

2 months ago - GlobeNewsWire

CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly

CHMP a dopts p ositive o pinion for Mycapssa ® for the t reatment of Acromegaly

2 months ago - GlobeNewsWire

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain

Amryt R eceives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain

2 months ago - GlobeNewsWire

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022

2 months ago - GlobeNewsWire

Can Amryt Pharma PLC Sponsored ADR (AMYT) Climb 187% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Amryt Pharma PLC Sponsored ADR (AMYT) points to an 187.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong a...

3 months ago - Zacks Investment Research

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Amryt to Report Q2 2022 Results on August 4, 2022

DUBLIN, Ireland, and Boston MA, July 21 , 202 2 , Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for ra...

4 months ago - GlobeNewsWire

Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.

4 months ago - Zacks Investment Research

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Sy...

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the T reatment of C arcinoid S y ndrome

4 months ago - GlobeNewsWire

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022

Amryt Presents New Analys e s from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022

4 months ago - GlobeNewsWire

Results of Annual General Meeting

DUBLIN, Ireland, and Boston MA, July 1 , 202 2 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rar...

5 months ago - GlobeNewsWire

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

5 months ago - GlobeNewsWire